CentoScreen Centogene AG - the Rare Disease Company
Germany | 316 | 314 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Epilepsy Panel Centogene AG - the Rare Disease Company
Germany | 734 | 744 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Intellectual Disability Panel Centogene AG - the Rare Disease Company
Germany | 777 | 770 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Usher Syndrome Type IF Quest Diagnostics Nichols Institute San Juan Capistrano
United States | 1 | 1 | - T Targeted variant analysis
|
Hereditary Hearing Loss and Deafness Panel PreventionGenetics, part of Exact Sciences
United States | 360 | 222 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Usher Syndrome Panel PreventionGenetics, part of Exact Sciences
United States | 11 | 12 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Usher Syndrome Type 1 and Deafness, Autosomal Recessive 23 (DFNB23) via the PCDH15 Gene PreventionGenetics, part of Exact Sciences
United States | 3 | 1 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
USHER SYNDROME TYPE 1F BioReference Health
United States | 1 | 1 | - T Targeted variant analysis
|
Super Panel Plus NxGen MDx
United States | 116 | 117 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Universal Panel Plus NxGen MDx
United States | 21 | 22 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Super Panel 113 NxGen MDx
United States | 113 | 115 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 106 plus TSE Natera, Inc.
United States | 103 | 107 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 106 Natera, Inc.
United States | 103 | 106 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Plus TSE Natera, Inc.
United States | 265 | 275 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Natera, Inc.
United States | 265 | 274 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 137 plus TSE Natera, Inc.
United States | 135 | 138 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 137 Natera, Inc.
United States | 135 | 137 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Natera, Inc.
United States | 265 | 274 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Ashkenazi Jewish Diseases Asper Biogene Asper Biogene LLC
Estonia | 43 | 37 | - C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Foresight Myriad Genetics, Inc.
United States | 112 | 110 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
